The present invention provides, in part, compounds of Formula I:
and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.
本发明提供了部分式I的化合物及其药学上可接受的盐和N-
氧化物;其制备的过程和
中间体;以及其组合物和用途。本发明还提供了具有降低D1R失效的D1激动剂,具有相对于
多巴胺降低β-阻滞素招募活性的D1激动剂,当结合到D1R时与Ser188显著相互作用但与Ser202显著不相互作用的D1激动剂,当结合到D1R时与Asp103相互作用较弱且与Ser198相互作用较弱的D1激动剂,以及它们的用途。